<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456560</url>
  </required_header>
  <id_info>
    <org_study_id>AV650-019</org_study_id>
    <nct_id>NCT00456560</nct_id>
  </id_info>
  <brief_title>AV650 Drug-Drug Interaction Study</brief_title>
  <official_title>A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects that paroxetine and fluvoxamine have on&#xD;
      the way the body distributes, breakdowns and eliminates AV650. In addition, information about&#xD;
      any side effects that may occur will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of AV650</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AV650</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic contribution, if any, to AV650 metabolism</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV650</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18.5 to 29.9 kg/m2&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             12-lead ECG, and vital signs&#xD;
&#xD;
          -  Clinical laboratory evaluations within the reference range for the test laboratory&#xD;
&#xD;
          -  Negative test for selected drugs of abuse at Screening&#xD;
&#xD;
          -  Negative HBsAg and HIV antibody screens&#xD;
&#xD;
          -  Females of childbearing potential must be surgically sterile, post-menopausal for at&#xD;
             least one year, or using and effective method of contraception; females of child&#xD;
             bearing potential must have a negative serum pregnancy test at Screening and Day -1&#xD;
&#xD;
          -  Males must be either sterile or agree to use an approved method of contraception&#xD;
&#xD;
          -  Able to comprehend and willing to sign an Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical manifestations of significant metabolic, hepatic, renal,&#xD;
             hematological, pulmonary, cardiovascular, endocrine, gastrointestinal, urological,&#xD;
             neurological, psychiatric disorders, or cancer&#xD;
&#xD;
          -  History of inflammatory arthritis&#xD;
&#xD;
          -  History of symptomatic hypotension&#xD;
&#xD;
          -  History of severe physical injury, direct impact trauma, or neurological trauma within&#xD;
             6 months&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  History of bipolar or major depressive disorder&#xD;
&#xD;
          -  History of hypersensitivity or allergies to any drug compound&#xD;
&#xD;
          -  Known intolerance to benzodiazepines&#xD;
&#xD;
          -  Known intolerance to active and/or inactive ingredients in fluvoxamine or paroxetine&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection, except that appendectomy,&#xD;
             hernia repair, and/or cholecystectomy will be allowed&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  History of alcoholism, drug abuse, or drug addiction&#xD;
&#xD;
          -  Use of any nicotine-containing or nicotine-replacement products within 6 months of Day&#xD;
             -1&#xD;
&#xD;
          -  Participation in any other investigational study drug trial within 90 days of Day -1&#xD;
&#xD;
          -  Use of any prescription medications/products within 3 months of Day 1 unless deemed&#xD;
             acceptable by the PI&#xD;
&#xD;
          -  Received any vaccination or immunization within 1 month of Day -1&#xD;
&#xD;
          -  Use of any over-the-counter, non-prescription preparations within 7 days of Day -1&#xD;
&#xD;
          -  Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or&#xD;
             beverages with 72 hours of Day -1&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Donation of blood within 3 months of Day -1 or of plasma within 2 weeks of Screening&#xD;
&#xD;
          -  Receipt of blood products within 2 months of Day 1&#xD;
&#xD;
          -  Female subjects who are pregnant or nursing&#xD;
&#xD;
          -  Any acute or chronic condition that, in the opinion of the PI, would limit the&#xD;
             subject's ability to complete and/or participate in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Global Clinical Pharmacology Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>September 13, 2007</last_update_submitted>
  <last_update_submitted_qc>September 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

